JP Morgan Chase’s Neurocrine Biosciences NBIX Stock Holding History

JP Morgan Chase’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.4M	Buy	81,000 +51,000	+170%	+$6.77M	﹤0.01%	2633
2025 Q4	$4.25M	Buy	+30,000	New	+$4.35M	﹤0.01%	3472
2025 Q2	–	Sell	-57,000	Closed	-$6.3M	–	7452
2025 Q1	$6.3M	Hold	57,000	–	–	﹤0.01%	2956
2024 Q4	$7.78M	Buy	57,000 +27,000	+90%	+$3.34M	﹤0.01%	2942
2024 Q3	$3.46M	Hold	30,000	–	–	﹤0.01%	3516
2024 Q2	$4.13M	Buy	+30,000	New	+$4.11M	﹤0.01%	3178
2022 Q2	–	Sell	-4,000	Closed	-$375K	–	6731
2022 Q1	$375K	Buy	+4,000	New	+$339K	﹤0.01%	4872
2021 Q1	–	Sell	-400,000	Closed	-$38.3M	–	6240
2020 Q4	$38.3M	Sell	400,000 -60,000	-13%	-$5.8M	0.01%	1208
2020 Q3	$44.9M	Buy	+460,000	New	+$53.2M	0.01%	1029
2019 Q2	–	Sell	-83,600	Closed	-$7.37M	–	5916
2019 Q1	$7.37M	Buy	83,600 +38,600	+86%	+$3.23M	﹤0.01%	2295
2018 Q4	$3.21M	Buy	+45,000	New	+$4.31M	﹤0.01%	2915
2018 Q2	–	Sell	-30,000	Closed	-$2.49M	–	5630
2018 Q1	$2.49M	Buy	+30,000	New	+$2.53M	﹤0.01%	3107

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

JP Morgan Chase's NBIX Position: Q1 2026 in Review

JP Morgan Chase increased its Neurocrine Biosciences (NBIX) stake by 4.6% in Q1 2026, buying an estimated $32.1M and bringing the position to 5,442,067 shares worth $701M. The position accounts for 0.05% of the portfolio, ranked #334.

JP Morgan Chase first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. The position peaked at $738M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

JP Morgan Chase held 5,442,067 shares of Neurocrine Biosciences worth $701M as of Q1 2026.
JP Morgan Chase bought 241,711 Neurocrine Biosciences shares in Q1 2026, an estimated $32.1M.
Neurocrine Biosciences made up 0.05% of JP Morgan Chase's portfolio in Q1 2026, its #334 holding.
JP Morgan Chase first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
JP Morgan Chase's Neurocrine Biosciences position peaked at $738M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.